

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Edward L.G. Pryzdial	Confirmation No.:	4718
Application No.:	10/551,565	Group No.:	1654
Filed:	February 8, 2006	Examiner:	Bradley, Christina
For:	USE OF COAGULATION PROTEINS TO LYSE CLOTS		

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement dated March 21, 2008, Applicant hereby elects Group IV, encompassing claims 1, 3-6, 10-11, 14-17, and 20-23, drawn to a method of accelerating blood clot dissolution or a pharmaceutical composition comprising Factor Xay without traverse. In reply to the further requirement for election of species, Applicant elects, without traverse: (a) condition for treatment: thrombosis; (b) fibrinolytic agent: plasminogen activator; and (c) thrombin inhibitor: heparin.

The Examiner is authorized to charge any fee deficiencies or credit any overpayments associated with this submission to the Nixon Peabody LLP Deposit Account No. 50-0850. In the event that there are any questions concerning this response, or the application in general, the Examiner is respectfully urged to telephone the undersigned so that prosecution of the application can be expedited.

Respectfully submitted,

Date: April 17, 2008

/Stephen R. Duly/
David S. Resnick (Reg. No. 34,235)
Stephen R. Duly (Reg. No. 56,183)
Nixon Peabody LLP
100 Summer Street
Boston, MA 0 2110
(617) 345-6057 / 1270